
Convalescent plasma, hydroxychloroquine, and remdesivir among the potential COVID-19 treatment pathways being pursued.

Convalescent plasma, hydroxychloroquine, and remdesivir among the potential COVID-19 treatment pathways being pursued.

A study investigated the use of lopinavir-ritonavir for the potential treatment of hospitalized patients with severe COVID-19.

The trials demonstrated a significant decrease in 24-hour coughs per hour versus placebo at 12 and 24 weeks.

Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.

After a steady climb, a new study showed that death rates for melanoma in the United States have dropped over the last few years.

The announcement follows their previous commitment to offering COVID-19 testing at local hospitals.

Pediatricians stress the importance of understanding the effects of COVID-19 on children.

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).


Due to the increased need for albuterol inhalers in hospitals for COVID-19, shortages have been occurring in some areas of the country and will likely continue to affect supplies.

Increases in PrEP coverage were associated with reductions in HIV infections, a new study found.

Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.

The updated labeling recommends temporary discontinuation of SGLT2 inhibitors before scheduled surgery.

The FDA issued emergency use authorization of a rapid, point-of-care COVID-19 diagnostic test, developed by Cepheid, that has a detection time of approximately 45 minutes.

There is currently no scientific evidence suggesting that non-steroidal anti-inflammatory drug use could worsen COVID-19 in those infected.

A malaria drug that President Donald Trump said could possibly treat coronavirus disease (COVID-19) is already in short supply, according to ASHP. However, Teva said it will donate millions of tablets to US hospitals.

What new gaps will pharmacists need to fill?

The FDA previously approved sofosbuvir and velpatasvir to treat HCV in adults.

It’s my hope that 2020 is a profession changing year, starting with the schools of pharmacy.

Genentech is launching a phase 3 clinical trial evaluating tocilizumab (Actemra) plus standard of care for use in hospitalized adult patients with severe COVID-19 pneumonia.

Perspectives from pharmacy associations in the states hardest hit with the COVID-19 outbreak.

A CDC analysis of preliminary data suggests that COVID-19 complications can occur in adults of any age.

A study identified significant similarities between SARS-CoV and SARS-CoV-2.

We asked pharmacists from various settings around the country: “Why did you become a pharmacist, and what keeps you motivated?"

A recent study from China found that diarrhea was a prominent symptom among up to half of patients with COVID-19 during the outbreak in Wuhan.

From drug information to patient education, these apps can help you be better at everything that you do.

Dr. Reddy’s Laboratories has launched its ziprasidone mesylate 20 mg/mL for injection, the first generic version of Geodon (Pfizer) for injection.

A study evaluated the stability of COVID-19 compared with SARS-CoV-1.

When looking to grow business with supplement sales, pharmacists should first educate themselves.

Relieving symptoms and optimizing therapies for allergic rhinitis